Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases, launched today with a Series A financing exclusively by F-Prime ...

BOSTON, June 18, 2025--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of intractable neurological diseases, announced today that ...

Atalanta Therapeutics, a biotechnology company advancing RNA interference (RNAi) for the treatment of neurological diseases, announced the completion of a $97 million Series B funding to support Phase ...

Atalanta Therapeutics is pioneering RNA interference (RNAi) for the treatment of neurological diseases, having developed a proprietary platform that, for the first time enables RNAi to be deployed as ...

Big Pharma-backed Atalanta Therapeutics is ramping up for the clinical debut of the company’s lead epilepsy asset in the wake of new data showing the RNA therapy suppressed seizures in mice. Mice with ...

Atalanta Therapeutics Inc. has completed a $97 million series B financing to support its investigational RNA interference (RNAi) therapies for KCNT1-related epilepsy and Huntington’s disease toward ...

He currently serves as Chief Financial Officer and Treasurer at Atalanta Therapeutics, a biotechnology company developing treatments for diseases of the CNS using RNA interference, where he leads ...

- Doug Pagán joins as Chief Financial Officer & Chief Operating Officer, bringing deep financial, business strategy and RNAi expertise BOSTON--(BUSINESS WIRE)-- Atalanta Therapeutics, a biotechnology ...